
Camurus
600
SEK
-0,58 %
CAMX
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Mindre end 1K følgere
-0,58%
+1,78%
+6,1%
+0,17%
-7,19%
+9,39%
+355,24%
+490,55%
+892,95%
Camurus operates in biotechnology. The company runs as a research-based pharmaceutical company and develops and distributes products for the treatment of severe and chronic diseases. Diseases treated with the company's products include, for example, cancer, endocrine disorders, and patients with opioid dependence. Camurus runs development projects under its own auspices and in partnership with international pharmaceutical companies. The company is headquartered in Lund.
Læs mereMarkedsværdi
35,33 mia. SEK
Aktieomsætning
33,94 mio. SEK
Omsætning
1,72 mia.
EBIT %
30,63 %
P/E
77,12
Udbytteafkast, %
-
Finanskalender
13.2
2025
Årsrapport '24
15.5
2025
Delårsrapport Q1'25
27.5
2025
Generalforsamling '25
ViserAlle indholdstyper

Camurus AB: Camurus' fourth quarter and full year 2024 earnings above previous estimates
Camurus AB: Change in number of shares and votes in Camurus
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Camurus AB: Camurus' Nomination Committee appointed for the Annual General Meeting 2025
Camurus AB: Camurus to present at Jefferies London Healtcare Conference

Camurus, Audiocast with teleconference, Q3'24
Camurus AB: Camurus' Interim Report Third Quarter 2024
Camurus AB: Camurus provides regulatory update on the US NDA for CAM2029 in acromegaly
Camurus AB: Change in number of shares and votes in Camurus
Camurus AB: EMA positive opinion for orphan drug designation to Camurus' octreotide SC depot for the treatment of polycystic liver disease
Camurus AB: Exercise in Camurus' employee stock options program 2021/2024
